Pfizer Inc. on Tuesday forecast a bigger-than-expected drop in sales of its COVID-19 vaccine and treatment in 2023, intensifying investor concerns over demand for the products as governments cut orders and work through inventories.

Copenhagen-based Lundbeck revealed Wednesday that its migraine drug Vyepti (eptinezumab) failed to demonstrate statistical superiority over placebo at reducing the number of monthly migraine days.

The values of leading pharmaceutical brands have skyrocketed during the COVID-19 pandemic; Johnson & Johnson retains the top position.